Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on innovative immunology therapeutics [3] - The company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory diseases: rosnilimab and ANB032 [3] - AnaptysBio has a preclinical immune cell modulator portfolio and has developed two cytokine antagonists available for out-licensing [3] Upcoming Event - Daniel Faga, president and CEO of AnaptysBio, will present at Guggenheim's 6th Annual Biotechnology Conference [1] - The event will take place on February 7, 2024, at 9:30 AM ET / 6:30 AM PT in a fireside chat format [2] - A live webcast of the presentation will be available on the investor section of AnaptysBio's website, with a replay accessible for at least 30 days [2]